scispace - formally typeset
Search or ask a question
Institution

American Cancer Society

NonprofitAtlanta, Georgia, United States
About: American Cancer Society is a nonprofit organization based out in Atlanta, Georgia, United States. It is known for research contribution in the topics: Cancer & Population. The organization has 1339 authors who have published 3700 publications receiving 688166 citations. The organization is also known as: American Cancer Society, ACS & American Society for the Control of Cancer.


Papers
More filters
Journal ArticleDOI
TL;DR: This article examined 17 substance-abusing women's perceptions of their mothering practices in the context of a residential substance-abuse treatment program for women with children and pregnant women, using in-depth semistructured interviews and observations of treatment groups.
Abstract: This article examines 17 substance-abusing women's perceptions of their mothering practices in the context of a residential substance-abuse treatment program for women with children and pregnant women. Using in-depth semistructured interviews and observations of treatment groups, the participants' cultural knowledge about mothering is explored. Although the women in this study described how their substance-abusing lifestyle had a negative impact on their children, they also detailed practices that illustrated that they felt capable as parents. The women were silent about how race, gender, or class arrangements affected their lives; their stories, however, showed active avoidance and manipulation of the contemporary ideology of mothering.

154 citations

Journal ArticleDOI
Veda N. Giri1, Karen E. Knudsen1, William Kevin Kelly1, Heather H. Cheng2, Kathleen A. Cooney3, Michael S. Cookson4, William L. Dahut5, Scott Weissman6, Howard R. Soule7, Daniel P. Petrylak8, Adam P. Dicker1, Saud H. AlDubayan9, Amanda E. Toland10, Colin C. Pritchard2, Curtis A. Pettaway11, Mary B. Daly12, James L. Mohler13, J. Kellogg Parsons14, Peter R. Carroll15, Robert Pilarski10, Amie Blanco15, Ashley H. Woodson11, Alanna Kulchak Rahm, Mary-Ellen Taplin9, Thomas J. Polascik3, Brian T. Helfand16, Colette Hyatt1, Alicia K. Morgans17, Felix Y. Feng15, Michael Russell Mullane, Jacqueline Powers18, Raoul S. Concepcion19, Daniel W. Lin2, Richard C. Wender20, James Ryan Mark1, Anthony J. Costello21, Arthur L. Burnett22, Oliver Sartor23, William B. Isaacs22, Jianfeng Xu16, Jeffrey N. Weitzel24, Gerald L. Andriole25, Himisha Beltran9, Alberto Briganti, Lindsey Byrne10, Anne Calvaresi1, Thenappan Chandrasekar1, David Y.T. Chen12, Robert B. Den1, Albert Dobi26, E. David Crawford14, James A. Eastham27, Scott E. Eggener28, Matthew L. Freedman9, Marc B. Garnick9, Patrick T. Gomella5, Nathan Handley1, Mark D. Hurwitz1, Joseph K Izes1, R. Jeffrey Karnes29, Costas D. Lallas1, Lucia R. Languino1, Stacy Loeb30, Ana Maria Lopez1, Kevin R. Loughlin9, Grace L. Lu-Yao1, S. Bruce Malkowicz18, Mark Mann1, Patrick Mille1, Martin Miner31, Todd M. Morgan32, Jose Moreno, Lorelei A. Mucci9, Ronald E. Myers1, Sarah M. Nielsen28, Brock O'Neil33, Wayne H. Pinover34, Peter A. Pinto5, Wendy Poage, Ganesh V. Raj35, Timothy R. Rebbeck9, Charles J. Ryan36, Howard M. Sandler37, Matthew J. Schiewer1, E. Michael D. Scott, Brittany M. Szymaniak, William Tester1, Edouard J. Trabulsi1, Neha Vapiwala18, Evan Y. Yu2, Charnita Zeigler-Johnson1, Leonard G. Gomella1 
TL;DR: This multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era and includes optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches.
Abstract: PURPOSEGermline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies tha...

154 citations

Journal ArticleDOI
01 Aug 1990-Cancer
TL;DR: The findings support previous suggestions that the majority of cases diagnosed as MH represent T‐lineage‐associated hematolymphoid neoplasms, and that only a rare case will be of monocyte/macrophage origin.
Abstract: Malignant histiocytosis (MH) is a term that has been used to describe a syndrome in which there is a systemic proliferation of cells that have the cytologic appearance of atypical histiocytes. Biopsy materials from 15 patients with malignant lymphoma diagnosed as malignant histiocytosis in a previous study reported in 1975 were analyzed by a panel of antibodies and reclassified using current nosologic concepts of malignant lymphoma. The antibodies used comprised reagents detecting a formalin-resistant epitope on B-cells (L26), T-cells (anti-CD3, anti-leu 22 [CD43], and UCHL1 [CD45RO]), monocyte/macrophage-derived cells (KP1 [CD68]), as well as antibodies that detect leukocyte common antigen (PD7 [CD45RB]), and a formalin-resistant epitope of Ki-1 (Ber-H2 [CD30]). The authors found that nine lymphomas had a profile consistent with T-lineage, including six in which Ki-1 (CD30) was coexpressed, and two were B-lineage. Three lymphomas showed no specific lineage characteristics although two were Ki-1 (CD30) positive, and none had expression of KP1 (CD68). The 12 lymph node biopsy specimens showed a variety of patterns of involvement, including sinusoidal, paracortical, and diffuse; the spleens showed predominantly red pulp involvement. A 15th case was believed most consistent with a virus-associated hemophagocytic syndrome. These findings support previous suggestions that the majority of cases diagnosed as MH represent T-lineage-associated hematolymphoid neoplasms, and that only a rare case will be of monocyte/macrophage origin. It is suggested that the term MH be subsumed under the rubric of large cell lymphoma and unless there are compelling immunohistochemical data to support a histiocytic origin, that the term MH be abandoned in favor of a more accurate descriptive term, such as sinusoidal large cell lymphoma.

154 citations

Journal ArticleDOI
TL;DR: A systematic review and meta-analysis of case-control and prospective cohort studies showed a protective effect of ever breastfeeding against hormone receptor-negative breast cancers, which are more common in younger women and generally have a poorer prognosis than other subtypes of breast cancer.

153 citations

Journal ArticleDOI
TL;DR: The American Cancer Society (ACS) provided estimates on the number of new cancer cases and deaths, and compiles health statistics on the US Hispanic population as mentioned in this paper, including cancer incidence, mortality, and behaviors relevant to cancer using the most recent data on incidence from the National Cancer Institute's (NCI) Surveillance, Epidemiolgy, and End Results (SEER) Program, mortality data from National Center for Health Statistics, and behavioral information from the Behavior Risk Factor Surveillance System (BRFSS), YRBSS, and National Health Interview Survey [NHIS].)
Abstract: In this article, the American Cancer Society (ACS) provides estimates on the number of new cancer cases and deaths, and compiles health statistics on the US Hispanic population. The compiled statistics include cancer incidence, mortality, and behaviors relevant to cancer using the most recent data on incidence from the National Cancer Institute's (NCI) Surveillance, Epidemiolgy, and End Results (SEER) Program, mortality data from the National Center for Health Statistics, and behavioral information from the Behavior Risk Factor Surveillance System (Centers for Disease Control and Prevention's Behavioral Risk Factor Surveillance System [BRFSS], Youth Risk Behavior Surveillance System [YRBSS], and National Health Interview Survey [NHIS].) An estimated 67,400 new cases of cancer and 22,100 cancer deaths will occur among Hispanics in 2003. Hispanics have lower incidence and death rates from all cancers combined and from the four most common cancers (breast, prostate, lung and bronchus, and colon and rectum) than non-Hispanic whites. However, Hispanics have higher incidence and mortality rates from cancers of the stomach, liver, uterine cervix, and gallbladder, reflecting in part greater exposure to specific infectious agents and lower rates of screening for cervical cancer, as well as dietary patterns and possible genetic factors. Strategies for reducing cancer risk among Hispanics include further development of effective interventions to increase screening and physical activity, reductions in tobacco use and obesity, and the development and application of effective vaccines.

153 citations


Authors

Showing all 1345 results

NameH-indexPapersCitations
Walter C. Willett3342399413322
Meir J. Stampfer2771414283776
Frank B. Hu2501675253464
David J. Hunter2131836207050
Edward Giovannucci2061671179875
Irving L. Weissman2011141172504
Bernard Rosner1901162147661
Susan E. Hankinson15178988297
Paolo Boffetta148145593876
Jeffrey A. Bluestone14351577080
Richard D. Smith140118079758
Garth D. Illingworth13750561793
Brian E. Henderson13771269921
Ahmedin Jemal132500380474
Michael J. Thun12939279051
Network Information
Related Institutions (5)
University of Texas MD Anderson Cancer Center
92.5K papers, 4.7M citations

89% related

Memorial Sloan Kettering Cancer Center
65.3K papers, 4.4M citations

89% related

Fred Hutchinson Cancer Research Center
30.9K papers, 2.2M citations

88% related

Mayo Clinic
169.5K papers, 8.1M citations

86% related

University of California, San Francisco
186.2K papers, 12M citations

85% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202312
20228
2021202
2020239
2019222
2018194